Female androgenetic alopecia
Conditions
Interventions
Control Group:Topical 5% minoxidil foam
Joint Group:Oral Blood-Activating Hair Growth Capsules in combination with topical 5% minoxidil foam.
Sponsors
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
Eligibility
Sex/Gender
Female
Age
18 Years to 50 Years
Inclusion criteria
Inclusion criteria: 1. Those who meet thediagnosis criteria for female androgenetic alopecia; 2. Savin classification Grade I1 to II2; 3. Those who meet the diagnostic criteria for blood stasis obstructing the meridians syndrome in thediagnosis of androgenetic alopecia; 4. Age between 18-50 years old; 5. Willing to use the same shampoo and maintain the same hairstyle, hair length, and hair color during the study period; 6. Willing and able to complete the diary card during the study period; 7. Agree to effective contraception during the study period; 8. Understand the trial procedures and content, and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Congenital alopecia, cicatricial alopecia, lupus erythematosus alopecia, syphilitic alopecia, alopecia areata, trichotillomania, and other causes of hair loss; 2. Subjects with other active dermatological conditions, scalp diseases, or active scalp injuries that may affect the assessment of efficacy or safety. Subjects who have shaved their heads must not be enrolled until their hair has regrown and the investigator determines that it does not affect the assessment results; 3. Use within 2 weeks prior to enrollment of: - Minoxidil (topical or oral), finasteride, dutasteride; - Systemic use of corticosteroids or synthetic corticosteroids; - Anti-androgen drugs: flutamide, cyproterone acetate, spironolactone, estrogen, progesterone, cimetidine, or ketoconazole; - medicated shampoos or conditioners (medicated shampoos and conditioners refer to any prescription shampoos or conditioners, as well as any over-the-counter medicated shampoos or conditioners, e.g., Fengtian,,,Scalp X shampoos, etc.), or other personal care products that may affect hair growth; - Other medications that, in the investigator's judgment, may affect the assessment of efficacy in this study; 4. Subjects with cardiovascular diseases (e.g., myocardial infarction within 6 months prior to screening, unstable angina, acute coronary syndrome, NYHA III/VI grade left ventricular failure, arrhythmias, or uncontrolled hypertension), neurological, psychiatric, pulmonary, renal, hepatic, endocrine, metabolic, hematological, gastrointestinal diseases, or immunodeficiency that, in the investigator's judgment, may compromise the subject's safety or interfere with the interpretation of study results; 5. Abnormal findings in vital signs, electrocardiogram, thyroid function tests, complete blood count, liver and kidney function tests, or coagulation function tests during the screening period that are clinically significant and, in the investigator's judgment, may affect the safety assessment of the subject; 6. Pregnant or breastfeeding women; 7. History of hair transplantation; 8. Currently participating in other interventional clinical studies; 9. Known allergy to the investigational drug or its components; 10. Subjects deemed unsuitable for enrollment by the investigator.
Countries
China
Contacts
Public ContactCao Yi
The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Chinese Medicine)
Outcome results
None listed